$-0.26
(Market cap
$529 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.4
-
Debt to Equity
0
-
Book Value
$1.3
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
169,545,445
7 Years Aggregate
CFO
$-186.18 Mln
EBITDA
$-236.04 Mln
Net Profit
$-225.06 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cabaletta Bio (CABA)
| 42.5 | 14.7 | -18.5 | 108.0 | -38.7 | -21.7 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Cabaletta Bio (CABA)
| -3.5 | -89.8 | 145.4 | 144.1 | -69.6 | -10.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cabaletta Bio (CABA)
|
3.1 | 529.0 | 0.0 | -181.3 | -- | -112.4 | -- | 2.7 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Cabaletta Bio (CABA)
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB... co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Read more
-
Co-Founder, Chairman, CEO & President
Dr. Steven A. Nichtberger M.D.
-
Co-Founder, Chairman, CEO & President
Dr. Steven A. Nichtberger M.D.
-
Headquarters
Philadelphia, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cabaletta Bio (CABA)
What is the current share price of Cabaletta Bio Inc (CABA) Today?
The share price of Cabaletta Bio Inc (CABA) is $3.12 (NASDAQ) as of 28-Aug-2026 16:23 EDT. Cabaletta Bio Inc (CABA) has given a return of -38.72% in the last 3 years.
What is the current PB & PE ratio of Cabaletta Bio Inc (CABA)?
Since, TTM earnings of Cabaletta Bio Inc (CABA) is negative, P/E ratio is not available.
The P/B ratio of Cabaletta Bio Inc (CABA) is 2.73 times as on 28-Aug-2026, a 49 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.33 |
2.00 |
2024 |
-0.98 |
0.75 |
2023 |
-14.90 |
4.27 |
2022 |
-5.26 |
2.61 |
2021 |
-2.36 |
0.91 |
What is the 52 Week High and Low of Cabaletta Bio Inc (CABA)?
The 52-week high and low of Cabaletta Bio Inc (CABA) are Rs 4.23 and Rs 1.40 as of 30-Aug-2026.
What is the market cap of Cabaletta Bio Inc (CABA)?
Cabaletta Bio Inc (CABA) has a market capitalisation of $ 529 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cabaletta Bio Inc (CABA)?
Before investing in Cabaletta Bio Inc (CABA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.